壳核
多巴胺转运体
黑质
尾状核
纹状体
多巴胺能
心理学
帕金森病
多巴胺
定量磁化率图
伏隔核
神经科学
内科学
医学
磁共振成像
内分泌学
疾病
放射科
作者
Yuto Uchida,Hirohito Kan,Keita Sakurai,Shigeru Inui,Susumu Kobayashi,Yoshihiro Akagawa,Kazuyoshi Shibuya,Yoshino Ueki,Noriyuki Matsukawa
摘要
Abstract Objective The objective of this study was to assess the relationship between nigrostriatal magnetic susceptibility and dopamine transporter abnormality and their associations with behavioral and cognitive impairments in patients with Parkinson's disease (PD). Methods For this case‐control study, we enrolled 41 patients with PD and 20 age‐matched healthy controls. All participants underwent global physical and cognitive assessments, 3‐Tesla brain magnetic resonance imaging including quantitative susceptibility mapping (QSM; iron deposition measure), and 123 I‐N‐v‐fluoropropyl‐2b‐carbomethoxy‐3b‐(4‐iodophenyl) nortropane single‐photon emission computed tomography (dopamine transporter measure). We subdivided the striatum into the putamen, caudate nucleus, and nucleus accumbens and measured the nigrostriatal QSM values and dopamine transporter–specific binding ratios using an atlas‐based approach. Results The patients with PD had higher QSM values in the substantia nigra and subdivisions of the striatum than did the healthy controls. The striatal dopamine transporter–specific binding ratios were not correlated with the QSM values of the substantia nigra but were inversely correlated with those of the striatum (putamen, r = −0.478, P = 0.009; caudate nucleus, r = −0.462, P = 0.011). The QSM values of the putamen were positively correlated with motor parkinsonism scores (Movement Disorder Society Unified Parkinson's Disease Rating Scale, r = 0.505, P = 0.003), and those of the caudate nucleus were negatively correlated with cognitive impairment scores (Montreal Cognitive Assessment, r = −0.525, P < 0.001). Conclusions This study showed that striatal iron accumulations were correlated with dopaminergic deficits and neurophysiological signs in patients with PD, highlighting the potential of QSM as an auxiliary biomarker for parkinsonism and cognitive dysfunction. © 2020 International Parkinson and Movement Disorder Society
科研通智能强力驱动
Strongly Powered by AbleSci AI